

# Andrew Owen

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7094597/andrew-owen-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

298  
papers

6,663  
citations

41  
h-index

68  
g-index

320  
ext. papers

7,937  
ext. citations

5.7  
avg, IF

5.75  
L-index

#	Paper	IF	Citations
298	A living WHO guideline on drugs for covid-19. <i>BMJ, The</i> , <b>2020</b> , 370, m3379	5.9	275
297	Research capacity. Enabling the genomic revolution in Africa. <i>Science</i> , <b>2014</b> , 344, 1346-8	33.3	256
296	Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 48, e108-16	11.6	200
295	Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. <i>Molecular Cancer</i> , <b>2011</b> , 10, 37	42.1	166
294	Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2008</b> , 61, 914-8	5.1	155
293	HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. <i>Pharmacogenetics and Genomics</i> , <b>2010</b> , 20, 112-20	1.9	142
292	Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. <i>Clinical Infectious Diseases</i> , <b>2012</b> , 54, 724-32	11.6	129
291	Carbamazepine is not a substrate for P-glycoprotein. <i>British Journal of Clinical Pharmacology</i> , <b>2001</b> , 51, 345-9	3.8	111
290	The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2011</b> , 55, 4122-7	5.9	101
289	Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. <i>Tuberculosis</i> , <b>2007</b> , 87, 248-55	2.6	94
288	Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2013</b> , 57, 6366-9	5.9	92
287	Genetic variants of ABCB10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 204, 145-53	7	92
286	Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2007</b> , 60, 987-93	5.1	92
285	Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2011</b> , 66, 2092-8	5.1	87
284	Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells. <i>British Journal of Pharmacology</i> , <b>2008</b> , 153, 805-19	8.6	87
283	The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2003</b> , 33, 551-6	3.1	85
282	Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy. <i>Advanced Drug Delivery Reviews</i> , <b>2016</b> , 103, 144-156	18.5	80

281	Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. <i>Aids</i> , <b>2005</b> , 19, 2097-102	3.5	76
280	Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 108, 775-790	6.1	75
279	Transport of gabapentin by LAT1 (SLC7A5). <i>Biochemical Pharmacology</i> , <b>2013</b> , 85, 1672-83	6	75
278	Acridinediones: selective and potent inhibitors of the malaria parasite mitochondrial bc1 complex. <i>Molecular Pharmacology</i> , <b>2008</b> , 73, 1347-55	4.3	73
277	Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir. <i>Clinical Infectious Diseases</i> , <b>2008</b> , 47, 1222-5	11.6	73
276	Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. <i>HIV Medicine</i> , <b>2009</b> , 10, 310-7	2.7	66
275	The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. <i>British Journal of Pharmacology</i> , <b>2009</b> , 156, 497-508	8.6	64
274	Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. <i>British Journal of Clinical Pharmacology</i> , <b>2005</b> , 59, 365-70	3.8	64
273	Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2010</b> , 54, 5242-50	5.9	63
272	Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation. <i>Advanced Healthcare Materials</i> , <b>2014</b> , 3, 400-11	10.1	62
271	Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study. <i>Clinical Pharmacology and Therapeutics</i> , <b>2015</b> , 98, 406-16	6.1	61
270	Lamotrigine is a substrate for OCT1 in brain endothelial cells. <i>Biochemical Pharmacology</i> , <b>2012</b> , 83, 805-14		60
269	Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance. <i>Pharmacogenetics and Genomics</i> , <b>2006</b> , 16, 439-50	1.9	58
268	Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV. <i>Clinical Pharmacokinetics</i> , <b>2015</b> , 54, 639-50	6.2	57
267	Multicomponent Organic Nanoparticles for Fluorescence Studies in Biological Systems. <i>Advanced Functional Materials</i> , <b>2012</b> , 22, 2469-2478	15.6	52
266	Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2011</b> , 55, 879-87	5.9	51
265	Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2014</b> , 69, 491-9	5.1	48
264	Divalent metals and pH alter raltegravir disposition in vitro. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2012</b> , 56, 3020-6	5.9	46

263	Expression of Pregnane-X-Receptor Transcript in Peripheral Blood Mononuclear Cells and Correlation with Mdr1 Mrna. <i>Antiviral Therapy</i> , <b>2004</b> , 9, 819-821	1.6	45
262	Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach. <i>Clinical Pharmacokinetics</i> , <b>2013</b> , 52, 583-92	6.2	43
261	The role of drug transporters in the kidney: lessons from tenofovir. <i>Frontiers in Pharmacology</i> , <b>2014</b> , 5, 248	5.6	43
260	Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2011</b> , 66, 1332-9	5.1	42
259	Long-acting injectable atovaquone nanomedicines for malaria prophylaxis. <i>Nature Communications</i> , <b>2018</b> , 9, 315	17.4	41
258	Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4. <i>Journal of Virology</i> , <b>2004</b> , 78, 12022-9	6.6	41
257	The implications of P-glycoprotein in HIV: friend or foe?. <i>Fundamental and Clinical Pharmacology</i> , <b>2005</b> , 19, 283-96	3.1	40
256	Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study. <i>Clinical Pharmacokinetics</i> , <b>2016</b> , 55, 861-873	6.2	38
255	Hyperbranched polydendrons: a new controlled macromolecular architecture with self-assembly in water and organic solvents. <i>Chemical Science</i> , <b>2014</b> , 5, 1844-1853	9.4	38
254	Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model. <i>Clinical Pharmacology and Therapeutics</i> , <b>2012</b> , 92, 494-502	6.1	38
253	Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. <i>Pharmacogenetics and Genomics</i> , <b>2010</b> , 20, 759-65	1.9	38
252	Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2010</b> , 65, 1889-93	5.1	38
251	Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir. <i>British Journal of Pharmacology</i> , <b>2008</b> , 155, 875-83	8.6	38
250	Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements. <i>British Journal of Clinical Pharmacology</i> , <b>2006</b> , 62, 237-42	3.8	38
249	Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , <b>2015</b> , 97, 298-306	6.1	36
248	Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2009</b> , 64, 1002-7	5.1	36
247	Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2012</b> , 56, 2959-66	5.9	36
246	Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies. <i>Nature Communications</i> , <b>2016</b> , 7, 13184	17.4	35

245	Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. <i>Pharmacogenetics and Genomics</i> , <b>2012</b> , 22, 10-9	1.9	35
244	Pharmacogenetics of HIV therapy. <i>Pharmacogenetics and Genomics</i> , <b>2006</b> , 16, 693-703	1.9	34
243	The mechanisms that control intracellular penetration of the HIV protease inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2003</b> , 51, 493-6	5.1	33
242	Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort. <i>PLoS ONE</i> , <b>2011</b> , 6, e16800	3.7	33
241	In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2021</b> , 76, 1874-1885	5.1	33
240	Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor. <i>Therapeutic Drug Monitoring</i> , <b>2013</b> , 35, 78-83	3.2	32
239	Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment. <i>Journal of Controlled Release</i> , <b>2015</b> , 219, 669-680	11.7	31
238	Tacrine-induced liver damage: an analysis of 19 candidate genes. <i>Pharmacogenetics and Genomics</i> , <b>2007</b> , 17, 1091-100	1.9	31
237	SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19		31
236	A living WHO guideline on drugs to prevent covid-19. <i>BMJ, The</i> , <b>2021</b> , 372, n526	5.9	31
235	New approaches to antiretroviral drug delivery: challenges and opportunities associated with the use of long-acting injectable agents. <i>Drugs</i> , <b>2014</b> , 74, 7-13	12.1	30
234	Mediation of in vitro cytochrome p450 activity by common pharmaceutical excipients. <i>Molecular Pharmaceutics</i> , <b>2013</b> , 10, 2739-48	5.6	29
233	Inpatient and outpatient pharmacokinetic variability of raltegravir in the clinical setting. <i>Therapeutic Drug Monitoring</i> , <b>2012</b> , 34, 232-5	3.2	29
232	Inhibitory Effects of Commonly Used Excipients on P-Glycoprotein in Vitro. <i>Molecular Pharmaceutics</i> , <b>2018</b> , 15, 4835-4842	5.6	29
231	Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2015</b> , 70, 555-61	5.1	28
230	Hyperbranched polydendrons: a new nanomaterials platform with tuneable permeation through model gut epithelium. <i>Chemical Science</i> , <b>2015</b> , 6, 326-334	9.4	28
229	Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients. <i>Clinical Pharmacokinetics</i> , <b>2013</b> , 52, 543-53	6.2	28
228	Dissecting the relative contribution of OATP1B1-mediated uptake of xenobiotics into human hepatocytes using siRNA. <i>Xenobiotica</i> , <b>2013</b> , 43, 920-31	2	28

227	The biological challenges and pharmacological opportunities of orally administered nanomedicine delivery. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2018</b> , 12, 223-236	4.2	27
226	Mitochondria are sensors for HIV drugs. <i>Trends in Pharmacological Sciences</i> , <b>2005</b> , 26, 258-64	13.2	26
225	Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling. <i>Journal of Infectious Diseases</i> , <b>2019</b> , 219, 1735-1742	7	26
224	Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study. <i>Clinical Infectious Diseases</i> , <b>2015</b> , 61, 453-63	11.6	25
223	Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults. <i>Antiviral Therapy</i> , <b>2012</b> , 17, 861-8	1.6	25
222	Development of a transactivator in hepatoma cells that allows expression of phase I, phase II, and chemical defense genes. <i>American Journal of Physiology - Cell Physiology</i> , <b>2006</b> , 290, C104-15	5.4	25
221	A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets. <i>Journal of Immunological Methods</i> , <b>2003</b> , 274, 129-37	2.5	25
220	Controlled synthesis of calcium carbonate nanoparticles and stimuli-responsive multi-layered nanocapsules for oral drug delivery. <i>International Journal of Pharmaceutics</i> , <b>2020</b> , 574, 118866	6.5	25
219	Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz. <i>In Silico Pharmacology</i> , <b>2013</b> , 1, 4	4.3	24
218	A multi-system approach assessing the interaction of anticonvulsants with P-gp. <i>PLoS ONE</i> , <b>2013</b> , 8, e64854	3.7	24
217	Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics. <i>Therapeutic Delivery</i> , <b>2015</b> , 6, 469-90	3.8	23
216	Rilpivirine inhibits drug transporters ABCB1, SLC22A1, and SLC22A2 in vitro. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2013</b> , 57, 5612-8	5.9	23
215	ABCB1 single nucleotide polymorphisms (1236C>T, 2677G>T, and 3435C>T) do not affect transport activity of human P-glycoprotein. <i>Pharmacogenetics and Genomics</i> , <b>2013</b> , 23, 314-23	1.9	23
214	In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2005</b> , 314, 1202-9	4.7	23
213	Long-acting drugs and formulations for the treatment and prevention of HIV infection. <i>International Journal of Antimicrobial Agents</i> , <b>2021</b> , 57, 106220	14.3	23
212	A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19. <i>Nature Communications</i> , <b>2021</b> , 12, 5469	17.4	23
211	Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA. <i>Antiviral Therapy</i> , <b>2004</b> , 9, 819-21	1.6	23
210	Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 1670-1678	5.1	22

209	Branched copolymer-stabilised nanoemulsions as new candidate oral drug delivery systems.. <i>RSC Advances</i> , <b>2018</b> , 8, 12984-12991	3.7	22
208	Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 1031-6	5.1	22
207	Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding. <i>Pharmacogenomics</i> , <b>2012</b> , 13, 1501-22	2.6	22
206	Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2012</b> , 67, 671-4	5.1	22
205	The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 82, 185-98	3.8	22
204	Sound understanding of environmental, health and safety, clinical, and market aspects is imperative to clinical translation of nanomedicines. <i>Nanotoxicology</i> , <b>2017</b> , 11, 147-149	5.3	21
203	Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trial. <i>Clinical Infectious Diseases</i> , <b>2015</b> , 60, 1026-32	11.6	21
202	CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults. <i>Pharmacogenetics and Genomics</i> , <b>2014</b> , 24, 459-63	1.9	21
201	Regulation of CYP3A4 and CYP3A5 expression and modulation of "intracrine" metabolism of androgens in prostate cells by liganded vitamin D receptor. <i>Molecular and Cellular Endocrinology</i> , <b>2012</b> , 364, 54-64	4.4	21
200	The impact of pharmacogenetics on HIV therapy. <i>International Journal of STD and AIDS</i> , <b>2009</b> , 20, 145-51	1.4	21
199	Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 2078-2088	3.8	21
198	The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine. <i>Clinical Pharmacology and Therapeutics</i> , <b>2017</b> , 102, 529-536	6.1	20
197	Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	20
196	Facile synthesis of complex multi-component organic and organic/magnetic inorganic nanocomposite particles. <i>Journal of Materials Chemistry</i> , <b>2012</b> , 22, 24744		20
195	Sequence and gene expression of chloroquine resistance transporter (pfcrt) in the association of in vitro drugs resistance of Plasmodium falciparum. <i>Malaria Journal</i> , <b>2011</b> , 10, 42	3.6	20
194	Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies. <i>Nature Communications</i> , <b>2019</b> , 10, 1413	17.4	19
193	Special populations and pharmacogenetic issues in tuberculosis drug development and clinical research. <i>Journal of Infectious Diseases</i> , <b>2015</b> , 211 Suppl 3, S115-25	7	19
192	Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 67, 785-790	11.6	19

191	In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents. <i>Clinical Pharmacokinetics</i> , <b>2018</b> , 57, 255-266	6.2	19
190	Predicting intestinal absorption of raltegravir using a population-based ADME simulation. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2013</b> , 68, 1627-34	5.1	19
189	Nanomedicines for HIV therapy. <i>Therapeutic Delivery</i> , <b>2013</b> , 4, 153-6	3.8	19
188	Sensitive assessment of the virologic outcomes of stopping and restarting non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. <i>PLoS ONE</i> , <b>2013</b> , 8, e69266	3.7	19
187	Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug. <i>Annals of the Rheumatic Diseases</i> , <b>2006</b> , 65, 1390-3	2.4	19
186	Determining the relationship between nanoparticle characteristics and immunotoxicity: key challenges and approaches. <i>Nanomedicine</i> , <b>2016</b> , 11, 1447-64	5.6	19
185	Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, 1013-1019	5.1	18
184	Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 68, 446-452	11.6	18
183	Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , <b>2019</b> , 144, 101-109	5.7	18
182	Factors impacting the expression of membrane-bound proteins in lymphocytes from HIV-positive subjects. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2007</b> , 60, 685-9	5.1	18
181	Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter. <i>Frontiers in Pharmacology</i> , <b>2015</b> , 6, 78	5.6	17
180	Whole-blood cultures from renal-transplant patients stimulated ex vivo show that the effects of cyclosporine on lymphocyte proliferation are related to P-glycoprotein expression. <i>Transplantation</i> , <b>2004</b> , 77, 557-61	1.8	17
179	Towards a Maraviroc long-acting injectable nanoformulation. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , <b>2019</b> , 138, 92-98	5.7	17
178	Intracellular pharmacokinetics of antiretroviral agents. <i>Journal of HIV Therapy</i> , <b>2004</b> , 9, 97-101		17
177	Improving maraviroc oral bioavailability by formation of solid drug nanoparticles. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , <b>2019</b> , 138, 30-36	5.7	16
176	Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2015</b> , 70, 2816-22	5.1	15
175	Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systems. <i>Journal of Nanobiotechnology</i> , <b>2018</b> , 16, 22	9.4	15
174	Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	15



173	The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. <i>Biochemical and Biophysical Research Communications</i> , <b>2011</b> , 408, 344-9	3.4	15
172	Augmented Inhibition of CYP3A4 in Human Primary Hepatocytes by Ritonavir Solid Drug Nanoparticles. <i>Molecular Pharmaceutics</i> , <b>2015</b> , 12, 3556-68	5.6	14
171	Toxicity and inflammatory response in Swiss albino mice after intraperitoneal and oral administration of polyurethane nanoparticles. <i>Toxicology Letters</i> , <b>2016</b> , 246, 17-27	4.4	14
170	Towards depersonalized abacavir therapy: chemical modification eliminates HLA-B*57 : 01-restricted CD8+ T-cell activation. <i>Aids</i> , <b>2015</b> , 29, 2385-95	3.5	14
169	Nanomedicine: Not a case of One size fits all <i>Nano Today</i> , <b>2009</b> , 4, 382-384	17.9	14
168	LC determination of carbamazepine in murine brain. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2001</b> , 26, 573-7	3.5	14
167	Towards a rational design of solid drug nanoparticles with optimised pharmacological properties. <i>Journal of Interdisciplinary Nanomedicine</i> , <b>2016</b> , 1, 110-123	4	13
166	Partial mitigation of gold nanoparticle interactions with human lymphocytes by surface functionalization with a 'mixed matrix'. <i>Nanomedicine</i> , <b>2014</b> , 9, 2467-79	5.6	13
165	High-throughput nanoprecipitation of the organic antimicrobial triclosan and enhancement of activity against Escherichia coli. <i>Journal of Materials Chemistry B</i> , <b>2013</b> , 1, 4455-4465	7.3	13
164	Host determinants of antiretroviral drug activity. <i>Current Opinion in Infectious Diseases</i> , <b>2005</b> , 18, 543-9	5.4	13
163	The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2		13
162	Synthesis, nanoprecipitation and pH sensitivity of amphiphilic linear-dendritic hybrid polymers and hyperbranched-polydendrons containing tertiary amine functional dendrons. <i>Soft Matter</i> , <b>2015</b> , 11, 7003-15	3.6	12
161	Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, 1004-1012	5.1	12
160	Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC. <i>British Journal of Clinical Pharmacology</i> , <b>2009</b> , 68, 375-80	3.8	12
159	The relationships of ABCB1 3435C>T and CYP2B6 516G>T with high-density lipoprotein cholesterol in HIV-infected patients receiving Efavirenz. <i>Clinical Pharmacology and Therapeutics</i> , <b>2009</b> , 86, 204-11	6.1	12
158	Optimization of the synthetic parameters of lipid polymer hybrid nanoparticles dual loaded with darunavir and ritonavir for the treatment of HIV. <i>International Journal of Pharmaceutics</i> , <b>2020</b> , 588, 119794	6.5	12
157	Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,	5.9	11
156	Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 617-20	5.9	11

155	The Application of Nanotechnology to Drug Delivery in Medicine <b>2015</b> , 173-223		11
154	Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2013</b> , 62, 60-6	3.1	11
153	The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2011</b> , 7, 341-52	5.5	11
152	Effect of prototypical inducers on ligand activated nuclear receptor regulated drug disposition genes in rodent hepatic and intestinal cells. <i>Acta Pharmacologica Sinica</i> , <b>2010</b> , 31, 51-65	8	11
151	-Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and -Acetyl-Isoniazid Pharmacokinetics during Antituberculosis Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,	5.9	11
150	Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and target site concentrations derived from their established human pharmacokinetics		11
149	Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 110, 64-68	6.1	11
148	Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 805-811	5.1	11
147	Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	10
146	Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies. <i>European Journal of Pharmaceutical Sciences</i> , <b>2019</b> , 140, 105068	5.1	10
145	No relationship between drug transporter genetic variants and tenofovir plasma concentrations or changes in glomerular filtration rate in HIV-infected adults. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2015</b> , 68, e56-9	3.1	10
144	Class-specific relative genetic contribution for key antiretroviral drugs. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2015</b> , 70, 3074-9	5.1	10
143	Misoprostol-induced fever and genetic polymorphisms in drug transporters SLCO1B1 and ABCC4 in women of Latin American and European ancestry. <i>Pharmacogenomics</i> , <b>2015</b> , 16, 919-28	2.6	10
142	CYP2B6 516G>T (rs3745274) and smoking status are associated with efavirenz plasma concentration in a Serbian cohort of HIV patients. <i>Therapeutic Drug Monitoring</i> , <b>2014</b> , 36, 734-8	3.2	10
141	Is methanol really a bad solvent for poly(n-butyl methacrylate)? Low dispersity and high molecular weight polymers of n-butyl methacrylate synthesised via ATRP in anhydrous methanol. <i>Polymer Chemistry</i> , <b>2014</b> , 5, 3608-3616	4.9	10
140	Plasmodium falciparum strains harboring dihydrofolate reductase with the I164L mutation are absent in Malawi and Zambia even under antifolate drug pressure. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2008</b> , 52, 3883-8	5.9	10
139	Critical considerations for targeting colorectal liver metastases with nanotechnology. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , <b>2020</b> , 12, e1588	9.2	10
138	Single-dose immunisation with a multimerised SARS-CoV-2 receptor binding domain (RBD) induces an enhanced and protective response in mice. <i>FEBS Letters</i> , <b>2021</b> , 595, 2323-2340	3.8	10

137	Intracellular delivery of nano-formulated antituberculosis drugs enhances bactericidal activity. <i>Journal of Interdisciplinary Nanomedicine</i> , <b>2017</b> , 2, 146-156	4	9
136	Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 190-199	5.1	9
135	Detection of ABCC2, CYP2B6 and CYP3A4 in human peripheral blood mononuclear cells using flow cytometry. <i>Journal of Immunological Methods</i> , <b>2008</b> , 339, 270-4	2.5	9
134	Pharmacogenetics of antiretroviral agents. <i>Current Opinion in HIV and AIDS</i> , <b>2008</b> , 3, 288-95	4.2	9
133	Safety perspectives on presently considered drugs for the treatment of COVID-19. <i>British Journal of Pharmacology</i> , <b>2020</b> , 177, 4353-4374	8.6	9
132	Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?. <i>ACS Infectious Diseases</i> , <b>2021</b> , 7, 1317-1331	5.5	9
131	Multiple and Co-Nanoprecipitation Studies of Branched Hydrophobic Copolymers and AB Amphiphilic Block Copolymers, Allowing Rapid Formation of Sterically Stabilized Nanoparticles in Aqueous Media. <i>Macromolecules</i> , <b>2015</b> , 48, 1883-1893	5.5	8
130	Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions. <i>Nanomedicine</i> , <b>2015</b> , 10, 1407-21	5.6	8
129	Derivation of CYP3A4 and CYP2B6 degradation rate constants in primary human hepatocytes: A siRNA-silencing-based approach. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2018</b> , 33, 179-187	2.2	8
128	Stable, polymer-directed and SPION-nucleated magnetic amphiphilic block copolymer nanoprecipitates with readily reversible assembly in magnetic fields. <i>Nanoscale</i> , <b>2016</b> , 8, 7224-31	7.7	8
127	Meta-analysis of the effect of CYP2B6, CYP2A6, UGT2B7 and CAR polymorphisms on efavirenz plasma concentrations. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 3281-3290	5.1	8
126	Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective. <i>Future Virology</i> , <b>2013</b> , 8, 871-890	2.4	8
125	Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 640-647	5.1	8
124	Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study. <i>Pharmacogenetics and Genomics</i> , <b>2016</b> , 26, 381-9	1.9	8
123	Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates. <i>Pharmacology Research and Perspectives</i> , <b>2017</b> , 5, e00359	3.1	7
122	Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, 165-172	5.1	7
121	Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,	5.9	7
120	Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 200-204	5.1	7

119	The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes. <i>British Journal of Pharmacology</i> , <b>2010</b> , 159, 484-93	8.6	7
118	Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2007</b> , 60, 881-4	5.1	7
117	Detection and biochemical characterisation of a novel polymorphism in the human GSTP1 gene. <i>Biochimica Et Biophysica Acta - General Subjects</i> , <b>2007</b> , 1770, 1240-7	4	7
116	Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEMVBL, CEME1000, MDCKIIMRP1 and MDCKIIMRP2 cell lines. <i>Aids</i> , <b>2003</b> , 17, 2276-2278	3.5	7
115	Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding. <i>AAS Open Research</i> , <b>1</b> , 16	1.8	7
114	Impact of long-acting therapies on the global HIV epidemic. <i>Aids</i> , <b>2021</b> , 35, S137-S143	3.5	7
113	Chapter 12: The Challenge of Regulating Nanomedicine: Key Issues. <i>RSC Drug Discovery Series</i> , <b>2016</b> , 290-314	3.64	7
112	Sequential infection with influenza A virus followed by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to more severe disease and encephalitis in a mouse model of COVID-19		7
111	A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	6
110	Adipogenic gene variants in patients with HIV-associated lipodystrophy. <i>Pharmacogenetics and Genomics</i> , <b>2011</b> , 21, 76-83	1.9	6
109	The impact of host pharmacogenetics on antiretroviral drug disposition. <i>Current Infectious Disease Reports</i> , <b>2006</b> , 8, 401-8	3.9	6
108	Differential expression of human immunodeficiency virus coreceptors, by CEM, CEMVBL, and CEM E1000 cells. <i>Journal of Infectious Diseases</i> , <b>2003</b> , 187, 874-5; author reply 875-6	7	6
107	Neuroinvasion and Neurotropism by SARS-CoV-2 Variants in the K18-hACE2 Mouse. <i>Viruses</i> , <b>2022</b> , 14, 1020	6.2	6
106	Telmisartan reverses antiretroviral-induced adipocyte toxicity and insulin resistance in vitro. <i>Diabetes and Vascular Disease Research</i> , <b>2018</b> , 15, 233-242	3.3	5
105	Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 3003-3010	5.1	5
104	Lack of interaction of lopinavir solid drug nanoparticles with cells of the immune system. <i>Nanomedicine</i> , <b>2017</b> , 12, 2043-2054	5.6	5
103	Simulating Intestinal Transporter and Enzyme Activity in a Physiologically Based Pharmacokinetic Model for Tenofovir Disoproxil Fumarate. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	5
102	Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2012</b> , 67, 675-80	5.1	5

101	Drug-regulated expression of Plasmodium falciparum P-glycoprotein homologue 1: a putative role for nuclear receptors. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2008</b> , 52, 1438-45	5.9	5
100	Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro antiviral activity against SARS-CoV-2		5
99	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 628-639	5.1	5
98	Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 149-156	5.1	5
97	A physiologically based pharmacokinetic model to predict the superparamagnetic iron oxide nanoparticles (SPIONs) accumulation in vivo. <i>European Journal of Nanomedicine</i> , <b>2017</b> , 9,		4
96	A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, ofz035	1	4
95	Considerations for clinically-relevant nanomedicine therapies for chronic diseases. <i>Nanomedicine</i> , <b>2015</b> , 10, 3103-7	5.6	4
94	Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,	5.9	4
93	Interactions between tenofovir and nevirapine in CD4+ T cells and monocyte-derived macrophages restrict their intracellular accumulation. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2013</b> , 68, 2545-9	5.1	4
92	RXR gene variants are associated with HIV lipodystrophy. <i>Pharmacogenetics and Genomics</i> , <b>2013</b> , 23, 438-41	1.9	4
91	Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis <b>2020</b> ,		4
90	Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2021</b> , 76, 2121-2128	5.1	4
89	Towards a computational prediction of nanoparticle pharmacokinetics and distribution <b>2016</b> , 02,		4
88	Development and Commercialization of Nanocarrier-Based Drug Products <b>2016</b> , 697-734		4
87	Pharmacogenetics of nevirapine excretion into breast milk and infants' exposure through breast milk versus postexposure prophylaxis. <i>Pharmacogenomics</i> , <b>2016</b> , 17, 891-906	2.6	4
86	Anhydrous nanoprecipitation for the preparation of nanodispersions of tenofovir disoproxil fumarate in oils as candidate long-acting injectable depot formulations. <i>Nanoscale Advances</i> , <b>2019</b> , 1, 4301-4307	5.1	4
85	Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2 <b>2021</b> ,		4
84	The emerging role of physiologically based pharmacokinetic modelling in solid drug nanoparticle translation. <i>Advanced Drug Delivery Reviews</i> , <b>2018</b> , 131, 116-121	18.5	4

83	Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by c.516G>T Genotypes. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,	5.9	3
82	Emerging nanomedicine applications and manufacturing: progress and challenges. <i>Nanomedicine</i> , <b>2016</b> , 11, 577-80	5.6	3
81	Long-Acting Injectable Statins-Is It Time for a Paradigm Shift?. <i>Molecules</i> , <b>2019</b> , 24,	4.8	3
80	Reactions of hydrophobic organic nanoparticle mixtures in water: nanoparticle-on-nanoparticle oxidative dye bleaching. <i>Green Chemistry</i> , <b>2013</b> , 15, 1590	10	3
79	IFN- $\beta$ 74A>T genotype is associated with higher CCR5 expression in peripheral blood mononuclear cells from HIV+ patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2011</b> , 58, 442-5	3.1	3
78	Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics.. <i>EBioMedicine</i> , <b>2022</b> , 76, 103856	8.8	3
77	Handbook of Immunological Properties of Engineered Nanomaterials		3
76	Species Similarities and Differences in Pharmacokinetics and Distribution of Antiretroviral Drugs <b>2014</b> , 339-360		3
75	Influence of SLCO1B1 polymorphisms on lopinavir C in Serbian HIV/AIDS patients. <i>British Journal of Clinical Pharmacology</i> , <b>2020</b> , 86, 1289-1295	3.8	3
74	Viral neuroinvasion and neurotropism without neuronal damage in the hACE2 mouse model of COVID-19		3
73	Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance?. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2021</b> , 76, 2230-2233	5.1	3
72	Unlike Chloroquine, Mefloquine Inhibits SARS-CoV-2 Infection in Physiologically Relevant Cells.. <i>Viruses</i> , <b>2022</b> , 14,	6.2	3
71	Chasing COVID-19 chemotherapeutics without putting the cart before the horse. <i>British Journal of Clinical Pharmacology</i> , <b>2020</b> ,	3.8	2
70	Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 1259-1266	5.1	2
69	Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine. <i>Clinical Pharmacokinetics</i> , <b>2015</b> , 54, 107-16	6.2	2
68	A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2014</b> , 69, 3275-81	5.1	2
67	Current Progress in the Pharmacogenetics of Infectious Disease Therapy <b>2011</b> , 555-578		2
66	Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the CYP2B6 516 TT polymorphism. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2008</b> , 62, 1188-90	5.1	2

65	Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2.. <i>International Journal of Antimicrobial Agents</i> , <b>2022</b> , 106542	14.3	2
64	Lack of Ronapreve (REGN-CoV; casirivimab and imdevimab) virological efficacy against the SARS-CoV-2 Omicron variant (B.1.1.529) in K18-hACE2 mice. <b>2022</b> ,		2
63	Viral and antiretroviral dynamics in HIV mother-to-child transmission fluids (VADICT) [Protocol and data analysis plan for a cohort study. <i>Wellcome Open Research</i> ,4, 34	4.8	2
62	<b>2017</b> ,		2
61	In Vitro Determination of the Immunogenic Impact of Nanomaterials on Primary Peripheral Blood Mononuclear Cells. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	2
60	Single-dose immunisation with a multimerised SARS-CoV-2 receptor binding domain (RBD) induces an enhanced and protective response in mice		2
59	Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19. <i>Advanced Drug Delivery Reviews</i> , <b>2021</b> , 178, 113848	18.5	2
58	Nanodrugs in Medicine and Healthcare: Pulmonary, Nasal and Ophthalmic Routes, and Vaccination <b>2016</b> , 633-648		2
57	Nanostructures in Drug Delivery <b>2016</b> , 101-134		2
56	Validation of Computational Approaches for Antiretroviral Dose Optimization. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 3838-9	5.9	2
55	Pharmacogenetics of artemether-lumefantrine influence on nevirapine disposition: Clinically significant drug-drug interaction?. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 540-550	3.8	2
54	Redispersible nanosuspensions as a plausible oral delivery system for curcumin. <i>Food Hydrocolloids</i> , <b>2021</b> , 121, 107005	10.6	2
53	Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection. <i>Nanoscale</i> , <b>2021</b> , 13, 6410-6416	7.7	2
52	Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEM(VBL), CEM(E1000), MDCKII(MRP1) and MDCKII(MRP2) cell lines. <i>Aids</i> , <b>2003</b> , 17, 2276-8	3.5	2
51	Integrated pharmacokinetic modelling for accelerated nanomedicine translation. <i>European Journal of Nanomedicine</i> , <b>2017</b> , 9, 1-3		1
50	Pharmacokinetics of HIV therapies in pregnant patients: an update. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2020</b> , 16, 449-461	5.5	1
49	Plasmodium falciparum and dihydrofolate reductase I164L mutations in Africa. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 1722; author reply 1722-3	5.9	1
48	Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. <i>Clinical Pharmacokinetics</i> , <b>2006</b> , 45, 213-4; author reply 214-5	6.2	1

47	Integrase as a Novel Target for the Inhibition of Human Immunodeficiency Virus Type 1 Infection: Current Status and Future Perspectives71-96		1
46	Designing single trigger/dual-response release and degradation into amine-functional hyperbranched-polydendron nanoprecipitates. <i>Nanoscale Advances</i> , <b>2020</b> , 2, 5468-5477	5.1	1
45	CYP2B6*6 Genotype Specific Differences in Artemether-Lumefantrine Disposition in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , <b>2020</b> , 60, 351-360	2.9	1
44	Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz. <i>Pharmacogenetics and Genomics</i> , <b>2020</b> , 30, 96-106	1.9	1
43	Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria. <i>Aids</i> , <b>2021</b> , 35, 1919-1927	3.5	1
42	Evaluation of intranasal nafamostat or camostat for SARS-CoV-2 chemoprophylaxis in Syrian golden hamsters <b>2021</b> ,		1
41	Nanoparticle Toxicity: General Overview and Insights Into Immunological Compatibility <b>2016</b> , 425-442		1
40	History: Potential, Challenges, and Future Development in Nanopharmaceutical Research and Industry <b>2016</b> , 1-16		1
39	Scale-Up and cGMP Manufacturing of Nanodrug Delivery Systems for Clinical Investigations <b>2016</b> , 295-330		1
38	Nanoscale Drugs: A Key to Revolutionary Progress in Pharmacy and Healthcare <b>2016</b> , 17-42		1
37	Regulatory Issues in Nanomedicines <b>2016</b> , 497-520		1
36	A Practical Guide to Translating Nanomedical Products <b>2016</b> , 661-696		1
35	The Emergence of Nanopharmacy: From Biology to Nanotechnology and Drug Molecules to Nanodrugs <b>2016</b> , 43-62		1
34	Development and validation of an LC-MS/MS assay for the quantification of efavirenz in different biological matrices. <i>Bioanalysis</i> , <b>2016</b> , 8, 2125-34	2.1	1
33	Cytotoxic chemotherapy and the evolution of cellular and viral resistance to antiretroviral therapy in HIV- infected individuals with lymphoma. <i>HIV Clinical Trials</i> , <b>2016</b> , 17, 197-203		1
32	Development of a highly sensitive bioanalytical assay for the quantification of favipiravir <b>2021</b> ,		1
31	Unlike Chloroquine, mefloquine inhibits SARS-CoV-2 infection in physiologically relevant cells and does not induce viral variants		1
30	Optimisation and validation of a sensitive bioanalytical method for niclosamide <b>2021</b> ,		1



29	Nanopharmacy: Exploratory Methods for Polymeric Materials <b>2016</b> , 231-270		o
28	An Overview of Nanoparticle Biocompatibility for Their Use in Nanomedicine <b>2016</b> , 443-468		o
27	Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , <b>2021</b> , 22, 3	2.8	o
26	AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter. <i>Trials</i> , <b>2021</b> , 22, 487	2.8	o
25	Safety assessment of a new nanoemulsion-based drug-delivery system reveals unexpected drug-free anticoagulant activity. <i>Nanomedicine</i> , <b>2020</b> , 15, 1361-1373	5.6	
24	Opportunities and Challenges in Nanotechnology-enabled Antiretroviral Delivery. <i>Frontiers in Nanobiomedical Research</i> , <b>2016</b> , 205-239		
23	In vitro characterisation of solid drug nanoparticle compositions of efavirenz in a brain endothelium cell line. <i>Journal of Interdisciplinary Nanomedicine</i> , <b>2017</b> , 2, 157-169	4	
22	Prediction and optimization of photo-activated curcumin dosage schedule in human, a promising antimicrobial candidate: A physiologically-based pharmacokinetic (PBPK) modeling. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , <b>2018</b> , WCP2018, PO1-11-30		o
21	Development of Prodrug Approaches for Long-Acting Nanoformulations of Emtricitabine-Based Regimens. <i>FASEB Journal</i> , <b>2018</b> , 32, 828.3		o.9
20	Nanoparticles for Imaging and Imaging Nanoparticles: State of the Art and Current Prospects <b>2016</b> , 533-560		
19	Overview and Presentation of Exploratory Methods for Manufacturing Nanoparticles/Inorganic Materials <b>2016</b> , 271-294		
18	Occupational Safety and Health <b>2016</b> , 331-354		
17	Micro- and Nano-Tools in Drug Discovery <b>2016</b> , 355-378		
16	Drug Targeting in Nanomedicine and Nanopharmacy: A Systems Approach <b>2016</b> , 403-424		
15	Translation to the Clinic: Preclinical and Clinical Pharmacology Studies of Nanoparticles – The Translational Challenge <b>2016</b> , 469-496		
14	Social Studies of Nanopharmaceutical Research <b>2016</b> , 521-532		
13	Nanoparticle-Based Physical Methods for Medical Treatments <b>2016</b> , 561-578		
12	Nanodrugs in Medicine and Healthcare: Oral Delivery <b>2016</b> , 579-602		

- 11 Steroidal Nanodrugs Based on Pegylated Nanoliposomes Remote Loaded with Amphipathic Weak Acids Steroid Prodrugs as Anti-Inflammatory Agents **2016**, 603-632
- 10 Future Outlook of Nanopharmacy: Challenges and Opportunities **2016**, 735-742
- 9 Omics-Based Nanopharmacy: Powerful Tools Toward Precision Medicine **2016**, 81-100
- 8 Characterization Methods: Physical and Chemical Characterization Techniques **2016**, 135-156
- 7 Nanoparticle Characterization Methods: Applications of Synchrotron and Neutron Radiation **2016**, 157-174
- 6 Understanding and Characterizing Functional Properties of Nanoparticles **2016**, 63-80
- 5 Overview of Techniques and Description of Established Processes **2016**, 175-230
- 4 Neurodegenerative Diseases [Alzheimer's Disease **2016**, 649-660
- 3 In vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel. *HIV Medicine*, **2021**, 22, 898-906 2.7
- 2 Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry. *Wellcome Open Research*, **6**, 246 4.8
- 1 Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry. *Wellcome Open Research*, **6**, 246 4.8